Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|June 20, 2017

Bio-Rad Launches Assay Kit for Zika, Dengue, and Chikungunya Detection

The RT-PCR kit can simultaneously screen samples for Zika, dengue, and chikungunya arbovirus RNAs.

On June 6, 2017, Bio-Rad launched a RT-PCR kit that allows researchers to simultaneously screen samples for Zika, dengue, and chikungunya arbovirus RNAs. The assay comes with the controls researchers need to internally validate the results. According to the company, this assay is approved for research use only and is currently available only outside the United States.

The ZDC Multiplex RT-PCR Assay (Research Use Only) is a one-step reverse-transcription, real-time PCR assay for the simultaneous detection and quantification of Zika, dengue, and chikungunya arbovirus RNAs from a range of specimen types.

“Our assay provides researchers an effective and reliable tool for the concurrent detection of Zika, dengue, and chikungunya RNAs in a single reaction tube,” said Luca Boveri, PhD, Bio-Rad global product manager, Gene Expression, in a statement. “Researchers can now rely on a wet-lab validated tool whose key components have been manufactured in GMP-approved facilities and extensively tested to generate consistent results.”

Source: Bio-Rad


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.